Almost 40 years after an adcomm's warning: FDA and sponsors withdraw approval for anabolic steroid

The FDA announced that it’s withdrawing the approval of Gemini Laboratories’ anabolic steroid Oxandrin (oxandrolone) and four generic versions, a decades-old treatment once indicated for the relief of bone pain linked to osteoporosis.

Oxandrin first won FDA approval in 1964. Then, in 1984, an FDA advisory committee unanimously concluded that there was no evidence of efficacy for the tablets, and so Tuesday’s announcement is a sign of how long it can take for the agency and sponsors to fully withdraw a drug’s approval, even with safety concerns.

Preview

来源: EndPoints

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP

LOG IN

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。